Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga-FAP-RGD PET/CT in Cancer Patients
NCT05515783Phase 2Completed
- Sponsor
- The First Hospital of Fujian Medical University
- Start
- May 2022
- Primary completion
- Sep 2024
- Modality
- Antibody-Radionuclide Conjugates, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
A Phase 2 trial of 68Ga-FAPI-RGD in solid tumor, sponsored by The First Hospital of Fujian Medical University. Started May 2022; status: completed.
02
Drugs
68Ga-FAPI-RGD
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05515783.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05515783.